A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a groundbreaking advance in influenza therapy, according to a study by the Institute for Biomedical Sciences at Georgia State University.
The antiviral drug blocks RNA polymerase, the enzyme that plays a central role in replicating the genome of influenza virus, causing mutations in the viral genome. If enough mutations occur, the genome becomes nonfunctional and the virus cannot replicate. The findings were published online on Oct. 23 in Science Translational Medicine.
“The compound is highly efficacious against influenza,” said Dr. Richard Plemper, senior author of the study and a professor in the Institute for Biomedical Sciences. “It’s orally available, it’s broad spectrum against all influenza virus strains tested, and most important it establishes a high barrier against viral escape from inhibition.”
Influenza, caused by a contagious respiratory virus, is characterized by fever, cough, headache, muscle and joint pain, severe malaise, sore throat and sometimes gastrointestinal symptoms. Patients in higher risk groups, such as older adults and individuals with compromised immune systems, frequently require hospitalization. Each year, seasonal influenza results in 30,000 to 80,000 fatalities in the United States. The seasonal flu vaccine is only moderately effective, and licensed antivirals are compromised by rapidly emerging viral resistance to the drugs.
In the study, the new antiviral drug was tested in ferrets, the most informative animal model for human influenza disease, against various strains that include seasonal and pandemic viruses, such as the swine-origin influenza virus responsible for a 2009 pandemic. The researchers found that the antiviral drug efficiently inhibited replication of all of these strains. Virus burden dropped rapidly after treatment, and the duration of fever was significantly shorter in treated ferrets than in control animals that did not receive the drug.
“We think that the next generation of influenza antiviral drugs must not only be efficacious and safe, but also address the resistance problem,” said Dr. Mart Toots, first author of the study and a research assistant professor associated with Dr. Plemper’s lab in the Institute for Biomedical Sciences.
That is where the new drug comes in. Through a combination of conventional and ultra-deep sequencing, Toots has demonstrated in collaboration with Dr. Alex Greninger at the University of Washington that it is very challenging for the virus to find a viable way to avoid the compound.
“We have not identified specific resistance mutations yet and are confident to say that the genetic barrier against viral resistance is high,” Plemper said. “We believe that this compound has high clinical potential as a next-generation influenza drug that combines key antiviral features.”
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Nearly a half-million poultry deaths: There are 3 avian influenza outbreaks in Victoria. Should we be worried?on October 7, 2020 at 7:31 am
As we navigate a global human pandemic, avian influenza (or "bird flu") has been detected in domestic poultry across Victoria.
- Comparing COVID-19 and seasonal influenza ahead of flu season, COVID-19 proves more deadly and infectiouson October 6, 2020 at 11:00 pm
PORTLAND, OR (KPTV) – President Donald Trump tweeted Tuesday "Flu season is coming up! Many people every year, sometimes over 100,000, and despite the Vaccine, die from the Flu. Are we going to close ...
- Nearly half a million poultry deaths: there are 3 avian influenza outbreaks in Victoria. Should we be worried?on October 6, 2020 at 8:07 pm
Victoria currently has three avian influenza outbreaks across six farms. They are being treated as an emergency. Here's how authorities are responding.
- County health expert sounds alarm over flu, Influenza B shows up earlyon October 6, 2020 at 10:57 am
Hear from nurse who shared shocking weight loss photos A look at the potential long term effects of Covid-19 Wearing surgical mask may reduce COVID-19 infections up to 75% Sneeze guards are trending ...
- Influenza Vaccine May Provide Roadmap to Prevent COVID-19on October 6, 2020 at 7:36 am
Scientists are in the process of knowing whether influenza vaccination is an effective therapy that reduces cardiovascular risk, which may further help prevent fatal and nonfatal cardiovascular ...
- Europe Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel - ResearchAndMarkets.comon October 6, 2020 at 2:56 am
The "Europe Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity" report has been added ...
- Hospitalized COVID-19 patients are younger, healthier than influenza patients, study findson October 5, 2020 at 5:00 pm
Patients hospitalized with COVID-19 were more often male, younger, and had fewer underlying medical conditions than hospitalized influenza patients, a new study found.
- Hospitalized COVID-19 patients are younger, healthier than influenza patientson October 5, 2020 at 5:00 pm
Patients hospitalized with COVID-19 were more likely male, younger, and, in both the US and Spain, had fewer comorbidities and lower medication use than hospitalized influenza patients according to a ...
- Influenza vaccination may provide roadmap to prevent COVID-19 in CV disease patientson October 5, 2020 at 11:04 am
Seasonal influenza vaccine development and mass production, as well as three international influenza vaccine cardiovascular outcomes trials currently underway, may inform future efforts targeted at ...
- Global Influenza Vaccines Markets 2019-2020 & Forecast to 2028 - ResearchAndMarkets.comon October 5, 2020 at 2:54 am
The "Global Influenza Vaccines Market 2019-2028" report has been added to ResearchAndMarkets.com's offering. The global influenza vaccines market is predicted to grow at a CAGR of 6.20% during the ...
via Bing News